Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 6/2007

01-12-2007 | Review

Cells of the synovium in rheumatoid arthritis. Macrophages

Authors: Raimund W Kinne, Bruno Stuhlmüller, Gerd-R Burmester

Published in: Arthritis Research & Therapy | Issue 6/2007

Login to get access

Abstract

The multitude and abundance of macrophage-derived mediators in rheumatoid arthritis and their paracrine/autocrine effects identify macrophages as local and systemic amplifiers of disease. Although uncovering the etiology of rheumatoid arthritis remains the ultimate means to silence the pathogenetic process, efforts in understanding how activated macrophages influence disease have led to optimization strategies to selectively target macrophages by agents tailored to specific features of macrophage activation. This approach has two advantages: (a) striking the cell population that mediates/amplifies most of the irreversible tissue destruction and (b) sparing other cells that have no (or only marginal) effects on joint damage.
Appendix
Available only for authorised users
Literature
1.
Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 115-124. 10.1002/art.1780390116.PubMed
2.
Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. Rheumatoid Arthritis. Edited by: Firestein GS, Panayi GS, Wollheim FA. 2006, New York: Oxford University Press, 55-75.
3.
Smolen JS, Steiner G: Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003, 2: 473-488. 10.1038/nrd1109.PubMed
4.
Stuhlmüller B, Ungethüm U, Scholze S, Martinez L, Backhaus M, Kraetsch HG, Kinne RW, Burmester GR: Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2000, 43: 775-790. 10.1002/1529-0131(200004)43:4<775::AID-ANR8>3.0.CO;2-7.PubMed
5.
Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, Oda H: Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004, 50: 1935-1938. 10.1002/art.20268.PubMed
6.
Lavagno L, Gunella G, Bardelli C, Spina S, Fresu LG, Viano I, Brunelleschi S: Anti-inflammatory drugs and tumor necrosis factor-alpha production from monocytes: role of transcription factor NF-kappaB and implication for rheumatoid arthritis therapy. Eur J Pharmacol. 2004, 501: 199-208. 10.1016/j.ejphar.2004.07.101.PubMed
7.
Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN: Anti-TNF therapy: where have we got to in 2005?. J Autoimmun. 2005, 25 (Suppl): 26-28. 10.1016/j.jaut.2005.09.006.PubMed
8.
van Rooijen N, Kesteren-Hendrikx E: 'In vivo ' depletion of macrophages by liposome-mediated 'suicide'. Methods Enzymol. 2003, 373: 3-16.PubMed
9.
Sweeney SE, Firestein GS: Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol. 2004, 16: 231-237. 10.1097/00002281-200405000-00011.PubMed
10.
Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, Limburg PC: Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther. 2004, 6: R384-R392. 10.1186/ar1204.PubMedCentralPubMed
11.
12.
Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak PP: Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 834-838. 10.1136/ard.2004.029751.PubMedCentralPubMed
13.
Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005, 5: 953-964. 10.1038/nri1733.PubMed
14.
Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003, 108: 2957-2963. 10.1161/01.CIR.0000099844.31524.05.PubMed
15.
Monaco C, Andreakos E, Kiriakidis S, Feldmann M, Paleolog E: T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy. 2004, 3: 35-42. 10.2174/1568010043483881.PubMed
16.
Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in the pathogenesis of rheumatoid arthritis. Rheumatoid Arthritis: The New Frontiers in Pathogenesis and Treatment. Edited by: Wollheim F, Firestein GS, Panayi GS. 2000, Oxford: Oxford University Press, 69-87.
17.
Chomarat P, Rissoan MC, Pin JJ, Banchereau J, Miossec P: Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. J Immunol. 1995, 155: 3645-3652.PubMed
18.
Scott BB, Weisbrot LM, Greenwood JD, Bogoch ER, Paige CJ, Keystone EC: Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis Rheum. 1997, 40: 490-498. 10.1002/art.1780400315.PubMed
19.
McInnes IB, Leung BP, Liew FY: Cell-cell interactions in synovitis: Interactions between T lymphocytes and synovial cells. Arthritis Res. 2000, 2: 374-378. 10.1186/ar115.PubMedCentralPubMed
20.
Burger D, Dayer JM: The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res. 2002, 4: S169-S176. 10.1186/ar558.PubMedCentralPubMed
21.
Sebbag M, Parry SL, Brennan FM, Feldmann M: Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol. 1997, 27: 624-632. 10.1002/eji.1830270308.PubMed
22.
Tran CN, Lundy SK, Fox DA: Synovial biology and T cells in rheumatoid arthritis. Pathophysiology. 2005, 12: 183-189. 10.1016/j.pathophys.2005.07.005.PubMedCentralPubMed
23.
Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF: CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol. 2004, 173: 6418-6426.PubMed
24.
Miossec P: An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol. 2004, 16: 218-222. 10.1097/00002281-200405000-00009.PubMed
25.
Lundy SK, Sarkar S, Tesmer LA, Fox DA: Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther. 2007, 9: 202-10.1186/ar2107.PubMedCentralPubMed
26.
Giles JT, Bathon JM: Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med. 2004, 19: 320-334. 10.1177/0885066604267854.PubMed
27.
Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN: The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006, 33: 2398-2408.PubMed
28.
Hopkins PA, Fraser JD, Pridmore AC, Russell HH, Read RC, Sriskandan S: Superantigen recognition by HLA class II on monocytes up-regulates toll-like receptor 4 and enhances proinflammatory responses to endotoxin. Blood. 2005, 105: 3655-3662. 10.1182/blood-2004-07-2523.PubMed
29.
Seibl R, Kyburz D, Lauener RP, Gay S: Pattern recognition receptors and their involvement in the pathogenesis of arthritis. Curr Opin Rheumatol. 2004, 16: 411-418. 10.1097/01.bor.0000127108.08398.34.PubMed
30.
Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, Hantzschel H, Michel BA, Gay RE, Gay S, et al: Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol. 2004, 172: 1256-1265.PubMed
31.
Frasnelli ME, Tarussio D, Chobaz-Peclat V, Busso N, So A: TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther. 2005, 7: R370-R379. 10.1186/ar1494.PubMedCentralPubMed
32.
Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, Yoshikawa H, Nagata S: Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature. 2006, 443: 998-1002. 10.1038/nature05245.PubMed
33.
Cutolo M, Lahita RG: Estrogens and arthritis. Rheum Dis Clin North Am. 2005, 31: 19-27. 10.1016/j.rdc.2004.10.001.PubMed
34.
Keith JC, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steffan RJ, Harnish DC: The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kB transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R427-R438. 10.1186/ar1692.PubMedCentralPubMed
35.
Taylor PC: Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des. 2003, 9: 1095-1106. 10.2174/1381612033454991.PubMed
36.
Wong PK, Campbell IK, Robb L, Wicks IP: Endogenous IL-11 is pro-inflammatory in acute methylated bovine serum albumin/interleukin-1-induced (mBSA/IL-1)arthritis. Cytokine. 2005, 29: 72-76. 10.1016/j.cyto.2004.09.011.PubMed
37.
Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995, 83: 793-802. 10.1016/0092-8674(95)90192-2.PubMed
38.
Georgopoulos S, Plows D, Kollias G: Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm. 1996, 46: 86-97.PubMed
39.
Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397.PubMed
40.
Firestein GS, Alvaro-Gracia JM, Maki R, Alvaro-Garcia JM: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990, 144: 3347-3353.PubMed
41.
Klimiuk PA, Goronzy JJ, Björ nsson J, Beckenbaugh RD, Weyand CM: Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol. 1997, 151: 1311-1319.PubMedCentralPubMed
42.
Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J: Serum cytokines in different histological variants of rheumatoid arthritis. J Rheumatol. 2001, 28: 1211-1217.PubMed
43.
van den Berg WB, Joosten LA, Kollias G, Van De Loo FA: Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis. 1999, 58: I40-I48.PubMedCentralPubMed
44.
Kollias G: Modeling the function of tumor necrosis factor in immune pathophysiology. Autoimmun Rev. 2004, 3: S24-S25.PubMed
45.
Toh ML, Marotte H, Blond JL, Jhumka U, Eljaafari A, Mougin B, Miossec P: Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis Rheum. 2006, 54: 2109-2118. 10.1002/art.21926.PubMed
46.
Lequerré T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq O, Daveau M, Mejjad O, Daragon A, Tron F, et al: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther. 2006, 8: R105-10.1186/ar1924.PubMedCentralPubMed
47.
Alsalameh S, Winter K, Al-Ward R, Wendler J, Kalden JR, Kinne RW: Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol. 1999, 49: 278-285. 10.1046/j.1365-3083.1999.00458.x.PubMed
48.
Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter R, Kinne RW: Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF-alpha in early-passage synovial fibroblasts via tumor necrosis factor receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 1043-1051. 10.1136/ard.2006.062521.PubMedCentralPubMed
49.
Alsalameh S, Amin RJ, Kunisch E, Jasin HE, Kinne RW: Preferential induction of prodestructive matrix metalloproteinase-1 and proinflammatory interleukin 6 and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts via tumor necrosis factor receptor-55. J Rheumatol. 2003, 30: 1680-1690.PubMed
50.
Deng GM, Zheng L, Chan FK, Lenardo M: Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med. 2005, 11: 1066-1072. 10.1038/nm1304.PubMed
51.
Wood NC, Dickens E, Symons JA, Duff GW: In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol. 1992, 62: 295-300. 10.1016/0090-1229(92)90106-X.PubMed
52.
Arend WP, Malyak M, Guthridge CJ, Gabay C: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998, 16: 27-55. 10.1146/annurev.immunol.16.1.27.PubMed
53.
Dinarello CA: The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002, 20: S1-S13.PubMed
54.
Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN: Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 1992, 31: 801-809. 10.1093/rheumatology/31.12.801.PubMed
55.
Silvestri T, Pulsatelli L, Dolzani P, Frizziero L, Facchini A, Meliconi R: In vivo expression of inflammatory cytokine receptors in the joint compartments of patients with arthritis. Rheumatol Int. 2006, 26: 360-368. 10.1007/s00296-005-0586-x.PubMed
56.
McInnes IB, Liew FY: Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005, 1: 31-39. 10.1038/ncprheum0020.PubMed
57.
McInnes IB, Gracie JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol. 2004, 4: 392-397. 10.1016/j.coph.2004.04.003.PubMed
58.
Connell L, McInnes IB: New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2006, 20: 865-878. 10.1016/j.berh.2006.05.011.PubMed
59.
Gracie JA: Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol. 2004, 136: 402-404. 10.1111/j.1365-2249.2004.02475.x.PubMedCentralPubMed
60.
Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer JM, Bresnihan B: Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004, 63: 1393-1398. 10.1136/ard.2003.016428.PubMedCentralPubMed
61.
Dinarello CA: Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007, 27: 98-114.PubMed
62.
Vandenbroeck K, Alloza I, Gadina M, Matthys P: Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol. 2004, 56: 145-160. 10.1211/0022357022962.PubMed
63.
Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ: Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003, 198: 1951-1957. 10.1084/jem.20030896.PubMedCentralPubMed
64.
Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000, 164: 6166-6173.PubMed
65.
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25: 677-686. 10.1016/j.it.2004.09.015.PubMed
66.
Villarino AV, Hunter CA: Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther. 2004, 6: 225-233. 10.1186/ar1227.PubMedCentralPubMed
67.
Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N: Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004, 173: 1171-1178.PubMed
68.
Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP: Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis. 2003, 62: 715-721. 10.1136/ard.62.8.715.PubMedCentralPubMed
69.
Koch AE: Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis. 2003, 62: ii60-ii67. 10.1136/ard.62.suppl_2.ii60.PubMedCentralPubMed
70.
Morand EF, Leech M: Macrophage migration inhibitory factor in rheumatoid arthritis. Front Biosci. 2005, 10: 12-22. 10.2741/1501.PubMed
71.
Bresnihan B: Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clin Exp Rheumatol. 2002, 20: S32-S34.PubMed
72.
Dinarello CA: Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004, 4: 378-385. 10.1016/j.coph.2004.03.010.PubMed
73.
Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J: Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum. 1996, 39: 386-395. 10.1002/art.1780390306.PubMed
74.
Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M: Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 1994, 179: 1517-1527. 10.1084/jem.179.5.1517.PubMed
75.
Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988, 31: 784-788. 10.1002/art.1780310614.PubMed
76.
Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, et al: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006, 54: 2817-2829. 10.1002/art.22033.PubMed
77.
Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006, 8 (Suppl 2): S5-10.1186/ar1969.PubMedCentralPubMed
78.
Chu CQ, Field M, Abney E, Zheng RQ, Allard S, Feldmann M, Maini RN: Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol. 1991, 86: 380-386.PubMedCentralPubMed
79.
Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol. 1995, 76: 187-194. 10.1006/clin.1995.1114.PubMed
80.
Chen W, Wahl SM: TGF-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun. 2002, 5: 62-91.PubMed
81.
Mattey DL, Nixon N, Dawes PT, Kerr J: Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 1190-1194. 10.1136/ard.2004.031674.PubMedCentralPubMed
82.
Jou IM, Shiau AL, Chen SY, Wang CR, Shieh DB, Tsai CS, Wu CL: Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis Rheum. 2005, 52: 339-344. 10.1002/art.20746.PubMed
83.
Cronstein BN: Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. Arthritis Rheum. 2004, 50: 2041-2043. 10.1002/art.20374.PubMed
84.
Schmidt-Weber CB, Rittig M, Buchner E, Hauser I, Schmidt I, Palombo-Kinne E, Emmrich F, Kinne RW: Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. J Leukoc Biol. 1996, 60: 230-244.PubMed
85.
Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nürnberg E, Emmrich F: Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum. 1995, 38: 1777-1790. 10.1002/art.1780381211.PubMed
86.
Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, de Waal Malefijt MC, van de Putte LB, Storm G, van den Berg WB: Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 2000, 43: 1951-1959. 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K.PubMed
87.
Metselaar JM, van den Berg WB, Holthuysen AE, Wauben MH, Storm G, van Lent PL: Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis. 2004, 63: 348-353. 10.1136/ard.2003.009944.PubMedCentralPubMed
88.
Evans CH, Ghivizzani SC, Lechman ER: Lessons learned from gene transfer approaches. Arthritis Res. 1999, 1: 21-24. 10.1186/ar6.PubMedCentralPubMed
89.
Handel ML, Girgis L: Transcription factors. Best Pract Res Clin Rheumatol. 2001, 15: 657-675. 10.1053/berh.2001.0186.PubMed
90.
Firestein GS: Holy Grail for rheumatoid arthritis?. Arthritis Rheum. 2004, 50: 2381-2386. 10.1002/art.20468.PubMed
91.
Boissier MC, Bessis N: Therapeutic gene transfer for rheumatoid arthritis. Reumatismo. 2004, 56: 51-61.PubMed
92.
Huber LC, Pap T, Muller-Ladner U, Gay RE, Gay S: Gene targeting: roadmap to future therapies. Curr Rheumatol Rep. 2004, 6: 323-325. 10.1007/s11926-004-0001-8.PubMed
93.
Mueller RB, Skapenko A, Grunke M, Wendler J, Stuhlmuller B, Kalden JR, Schulze-Koops H: Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum. 2005, 52: 451-460. 10.1002/art.20863.PubMed
94.
Brinckerhoff CE, Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002, 3: 207-214. 10.1038/nrm763.PubMed
95.
Wang X, Liang J, Koike T, Sun H, Ichikawa T, Kitajima S, Morimoto M, Shikama H, Watanabe T, Sasaguri Y, et al: Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits. Am J Pathol. 2004, 165: 1375-1383.PubMedCentralPubMed
96.
Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley DE, Davis RW: Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA. 1997, 94: 2150-2155. 10.1073/pnas.94.6.2150.PubMedCentralPubMed
97.
O'Hara R, Murphy EP, Whitehead AS, Fitzgerald O, Bresnihan B: Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004, 50: 1788-1799. 10.1002/art.20301.PubMed
98.
Hahn G, Stuhlmuller B, Hain N, Kalden JR, Pfizenmaier K, Burmester GR: Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest. 1993, 91: 862-870.PubMedCentralPubMed
99.
Hamerlinck FF: Neopterin: a review. Exp Dermatol. 1999, 8: 167-176. 10.1111/j.1600-0625.1999.tb00367.x.PubMed
100.
Rosengren S, Hoffman H, Bugbee W, Boyle DL: Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis. 2005, 64: 708-714. 10.1136/ard.2004.025577.PubMedCentralPubMed
101.
Van Roon JA, Bijlsma JW, van De Winkel JG, Lafeber FP: Depletion of synovial macrophages in rheumatoid arthritis by an anti-Fc{gamma}RI-Calicheamicin immunoconjugate. Ann Rheum Dis. 2005, 64: 865-870. 10.1136/ard.2004.028845.PubMedCentralPubMed
102.
Wijngaarden S, van De Winkel JG, Jacobs KM, Bijlsma JW, Lafeber FP, Van Roon JA: A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 3878-3887. 10.1002/art.20672.PubMed
103.
Liu H, Pope RM: Phagocytes: mechanisms of inflammation and tissue destruction. Rheum Dis Clin North Am. 2004, 30: 19-39. 10.1016/S0889-857X(03)00107-8.PubMed
104.
Dao DN, Kremer L, Guerardel Y, Molano A, Jacobs WR, Porcelli SA, Briken V: Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infect Immun. 2004, 72: 2067-2074. 10.1128/IAI.72.4.2067-2074.2004.PubMedCentralPubMed
105.
Briken V, Porcelli SA, Besra GS, Kremer L: Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol. 2004, 53: 391-403. 10.1111/j.1365-2958.2004.04183.x.PubMed
106.
Mogensen TH, Paludan SR: Reading the viral signature by Toll-like receptors and other pattern recognition receptors. J Mol Med. 2005, 83: 180-192. 10.1007/s00109-004-0620-6.PubMed
107.
Itescu S: Rheumatic aspects of acquired immunodeficiency syndrome. Curr Opin Rheumatol. 1996, 8: 346-353. 10.1097/00002281-199607000-00012.PubMed
108.
Cheevers WP, Snekvik KR, Trujillo JD, Kumpula-McWhirter NM, Pretty On Top KJ, Knowles DP: Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis. Virology. 2003, 306: 116-125. 10.1016/S0042-6822(02)00044-2.PubMed
109.
Iguchi T, Kurosaka M, Ziff M: Electron microscopic study of HLA-DR and monocyte/macrophage staining cells in the rheumatoid synovial membrane. Arthritis Rheum. 1986, 29: 600-613. 10.1002/art.1780290504.PubMed
110.
Bresnihan B, Gogarty M, Fitzgerald O, Dayer JM, Burger D: Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?. Arthritis Res Ther. 2004, 6: R563-R566. 10.1186/ar1443.PubMedCentralPubMed
111.
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005, 23: 479-490. 10.1016/j.immuni.2005.09.015.PubMed
112.
Chen Q, Carroll HP, Gadina M: The newest interleukins: recent additions to the ever-growing cytokine family. Vitam Horm. 2006, 74: 207-228.PubMed
113.
Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007, 104: 282-287. 10.1073/pnas.0606854104.PubMedCentralPubMed
114.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA: Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005, 22: 131-142.PubMed
115.
Brennan F, Beech J: Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol. 2007, 19: 296-301. 10.1097/BOR.0b013e32805e87f1.PubMed
116.
Van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP: Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis. 2003, 62: 113-119. 10.1136/ard.62.2.113.PubMedCentralPubMed
117.
118.
Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN: IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA. 2003, 100: 125-130. 10.1073/pnas.0136772100.PubMedCentralPubMed
119.
Jüngel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA, Gay RE, Emmrich F, Gay S, et al: Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum. 2004, 50: 1468-1476. 10.1002/art.20218.PubMed
120.
Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, et al: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004, 5: 752-760. 10.1038/ni1084.PubMed
121.
Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP: The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum. 2003, 48: 1177-1189. 10.1002/art.10943.PubMed
122.
Romer J, Hasselager E, Norby PL, Steiniche T, Thorn CJ, Kragballe K: Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol. 2003, 121: 1306-1311. 10.1111/j.1523-1747.2003.12626.x.PubMed
123.
Liao SC, Cheng YC, Wang YC, Wang CW, Yang SM, Yu CK, Shieh CC, Cheng KC, Lee MF, Chiang SR, et al: IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol. 2004, 173: 6712-6718.PubMed
124.
Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, Brandt C, Jelinek L, Madden K, McKernan PA, et al: Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem. 2002, 277: 47517-47523. 10.1074/jbc.M205114200.PubMed
125.
Wolk K, Kunz S, Asadullah K, Sabat R: Cutting edge: immune cells as sources and targets of the IL-10 family members?. J Immunol. 2002, 168: 5397-5402.PubMed
126.
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: IL-22 increases the innate immunity of tissues. Immunity. 2004, 21: 241-254. 10.1016/j.immuni.2004.07.007.PubMed
127.
Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA: The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002, 168: 6041-6046.PubMed
128.
Vandenbroeck K, Cunningham S, Goris A, Alloza I, Heggarty S, Graham C, Bell A, Rooney M: Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2773-2778. 10.1002/art.11236.PubMed
129.
Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, Joosten LA, van den Berg WB: Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum. 2004, 50: 3856-3865. 10.1002/art.20678.PubMed
130.
Siren J, Pirhonen J, Julkunen I, Matikainen S: IFN-{alpha} Regulates TLR-Dependent Gene Expression of IFN-{alpha}, IFN-{beta}, IL-28, and IL-29. J Immunol. 2005, 174: 1932-1937.PubMed
131.
Miossec P, Naviliat M, Dupuy d'Angeac A, Sany J, Banchereau J: Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum. 1990, 33: 1180-1187. 10.1002/art.1780331112.PubMed
132.
Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM: Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol. 1993, 151: 4344-4351.PubMed
133.
Van Roon JA, Lafeber FP, Bijlsma JW: Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 2001, 44: 3-12. 10.1002/1529-0131(200101)44:1<3::AID-ANR2>3.0.CO;2-U.PubMed
134.
Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM: Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1388-1397. 10.1002/1529-0131(199808)41:8<1388::AID-ART7>3.0.CO;2-F.PubMed
135.
Klimiuk PA, Goronzy JJ, Weyand CM: IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol. 1999, 162: 4293-4299.PubMed
136.
Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, Reuss-Borst M: Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol. 2001, 28: 12-21.PubMed
137.
Kaufmann J, Franke S, Kientsch-Engel R, Oelzner P, Hein G, Stein G: Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology (Oxford). 2001, 40: 474-475. 10.1093/rheumatology/40.4.474.
138.
Lard LR, Roep BO, Toes RE, Huizinga TW: Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol. 2004, 31: 35-39.PubMed
139.
Tak PP: IFN-beta in rheumatoid arthritis. Front Biosci. 2004, 9: 3242-3247. 10.2741/1475.PubMed
140.
Mi Z, Ghivizzani SC, Lechman E, Glorioso JC, Evans CH, Robbins PD: Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees. Arthritis Res Ther. 2003, 5: R132-R139. 10.1186/ar745.PubMedCentralPubMed
Metadata
Title
Cells of the synovium in rheumatoid arthritis. Macrophages
Authors
Raimund W Kinne
Bruno Stuhlmüller
Gerd-R Burmester
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 6/2007
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2333

Other articles of this Issue 6/2007

Arthritis Research & Therapy 6/2007 Go to the issue

Review

Toll-like receptors and innate immune responses in systemic lupus erythematosus

Research article

Cross-sectional analysis of adverse outcomes in 1,029 pregnancies of Afro-Caribbean women in Trinidad with and without systemic lupus erythematosus

Research article

A critical appraisal of guidelines for the management of knee osteoarthritis using Appraisal of Guidelines Research and Evaluation criteria

Research article

Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study

Review

Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts

Research article

Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits